Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma
This study is currently recruiting participants.
Verified October 2012 by Cantonal Hospital of St. Gallen
Sponsor:
Cantonal Hospital of St. Gallen
Collaborators:
Celgene Corporation
Mundipharma Research GmbH & Co KG
Mundipharma Medical Company
Amgen
Information provided by (Responsible Party):
PD Dr. Ulrich Mey, Kantonsspital Graubünden
ClinicalTrials.gov Identifier:
NCT01701076
First received: September 27, 2012
Last updated: October 3, 2012
Last verified: October 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | March 2015 |
| Estimated Primary Completion Date: | March 2014 (Final data collection date for primary outcome measure) |